FRESENIUS KABI

Gadoterate Meglumine Injection, USP

FDA-approved, cost-effective generic gadolinium-based contrast agent (GBCA) is bioequivalent and fully substitutable to Dotarem®.*

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadoterate Meglumine Injection is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis

GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of Gadoterate Meglumine Injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- **The risk for NSF appears highest among patients with:**
  - **Chronic, severe kidney disease (GFR < 30 mL/min/1.73m^2), or**
  - **Acute kidney injury.**
- **Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.**
- **For patients at highest risk for NSF, do not exceed the recommended Gadoterate Meglumine Injection dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.**

Please see Important Safety Information on the following pages.

Gadoterate Meglumine Injection, USP

Macrocyclic & Ionic Gadolinium-Based Contrast Agent

Fresenius Kabi's FDA-approved generic Gadoterate Meglumine Injection, USP provides a cost-effective option that is bioequivalent and fully substitutable to Dotarem®.*

Gadoterate Meglumine Injection is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.[1,2]

The use of a gadolinium (Gd)-based contrast agent (GBCA) further increases the diagnostic sensitivity and capabilities of MRI. In the United States, GBCAs are used in 30% to 45% of the approximately 40 million MRI procedures performed each year.[3]

Generic medicines are the same high quality as their brand-name versions.[4]

Generic drugs go through a rigorous review process to receive FDA approval. The FDA ensures a generic medication provides the same clinical benefit and is as safe and effective as the brand-name medicine. Generic contrast agents are considered generic drugs by the FDA. To learn more about generic drugs visit **www.FDA.gov/GenericDrugs**.

A Cost-Effective Option from an Experienced, Reliable Supplier

Committed to Helping You

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition – with a comprehensive portfolio of injectable drugs and delivery systems used to treat a broad spectrum of patients. As a leading provider of generic medications, we leverage our 100-year history to deliver innovative therapies that are safe, effective and affordable. **That's how Fresenius Kabi brings confidence within reach.**

Sources:
1. Gadoterate Meglumine Injection, USP Single Dose Vial Package Insert, August 2024
2. Gadoterate Meglumine Injection, USP Pharmacy Bulk Package Insert, August 2024
3. Cheong BYC, Wilson JM, Preventza OA, Muthupillai R. Gadolinium-based contrast agents: updates and answers to typical questions regarding gadolinium use. Tex Heart Inst J 2022; 49(3):e217680. doi: 10.14503/THIJ-21-7680
4. FDA, Generic Drug Facts Handout https://www.fda.gov/media/107601/download

IMPORTANT SAFETY INFORMATION

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadoterate Meglumine Injection is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis

GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of Gadoterate Meglumine Injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- **The risk for NSF appears highest among patients with:**
  - **Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or**
  - **Acute kidney injury.**
- **Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.**
- **For patients at highest risk for NSF, do not exceed the recommended Gadoterate Meglumine Injection dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.**

Contraindications

Gadoterate Meglumine Injection is contraindicated in patients with history of clinically important hypersensitivity reactions to Gadoterate Meglumine Injection.

Warning and Precautions

Risk Associated with Intrathecal Use: Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of Gadoterate Meglumine Injection have not been established with intrathecal use. Gadoterate Meglumine Injection is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis: GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of Gadoterate Meglumine Injection among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.

Hypersensitivity Reactions: Anaphylactic and anaphylactoid reactions have been reported with Gadoterate Meglumine Injection, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. Monitor patients closely for need of emergency cardiorespiratory support.

Before Gadoterate Meglumine Injection administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to Gadoterate Meglumine Injection.

Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver and spleen). While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients

Fresenius Kabi's Gadoterate Meglumine Injection, USP is fully substitutable and chemically equivalent to Dotarem®.*

	Reference Listed Drug					Approved AP Generic					Therapeutically Equivalent
Name	**Dotarem®[1,2]**					**Gadoterate Meglumine Injection, USP[3,4]**					
Indication	Gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.					Gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.					✓
Features	Sterile, nonpyrogenic, clear, colorless to yellow, aqueous solution. No preservative is added.					Sterile, nonpyrogenic, clear, colorless to yellow, aqueous solution. No preservative is added.					✓
Concentration	0.5 mmol per mL (Each mL of Gadoterate Meglumine Injection, USP contains 376.9 mg of gadoterate meglumine)					0.5 mmol per mL (Each mL of Gadoterate Meglumine Injection, USP contains 376.9 mg of gadoterate meglumine)					✓
Ingredients	**Active Ingredient:** gadoterate meglumine **Inactive Ingredients:** DOTA, water for injection					**Active Ingredient:** gadoterate meglumine **Inactive Ingredients:** DOTA, water for injection					✓
Vial Presentations	5 mL Single Dose Vial	10 mL Single Dose Vial	15 mL Single Dose Vial	20 mL Single Dose Vial	100 mL Pharmacy Bulk Package	5 mL Single Dose Vial	10 mL Single Dose Vial	15 mL Single Dose Vial	20 mL Single Dose Vial	100 mL Pharmacy Bulk Package	✓
Concentration	2.5 mmol per mL	5 mmol per mL	7.5 mmol per mL	10 mmol per mL	50 mmol per mL	2.5 mmol per mL	5 mmol per mL	7.5 mmol per mL	10 mmol per mL	50 mmol per mL	✓
Parameter	**Value**					**Value**					✓
Density @20°C	1.1753 g/cm^3					1.1753 g/cm^3					✓
Viscosity @20°C	3.4 mPa·s					3.4 mPa·s					✓
Viscosity @37°C	2.4 mPa·s					2.4 mPa·s					✓
Osmolality	1,350 mOsm/kg water					1,350 mOsm/kg water					✓
Log K_{therm}	25.6					25.6					✓
Log K_{cond} (pH 7.4)	19.3					19.3					✓
Storage	Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).					Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F).					✓

1. Dotarem Single Dose Vial Package Insert, May 2024
2. Dotarem Pharmacy Bulk Package Insert, January 2024
3. Gadoterate Meglumine Injection, USP Single Dose Vial Package Insert, August 2024
4. Gadoterate Meglumine Injection, USP Pharmacy Bulk Package Insert, August 2024

requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.

Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.

Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of Gadoterate Meglumine Injection. Extravasation into tissues during Gadoterate Meglumine Injection administration may result in tissue irritation.

Adverse Reactions
The most frequent (≥ 0.2%) adverse reactions in clinical studies were nausea, headache, injection site pain, injection site coldness, and rash.

Serious adverse reactions in the Postmarketing experience have been reported with Gadoterate Meglumine Injection. These serious adverse reactions include but are not limited to arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma, convulsion, and acute pancreatitis with onset within 48 hours after GBCA administration.

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Use in Specific Populations
Pregnancy: GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.

Lactation: There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.

Pediatric Use: The safety of Gadoterate Meglumine Injection has not been established in preterm neonates. No dosage adjustment according to age is necessary in pediatric patients.

Geriatric Use: Use of Gadoterate Meglumine Injection in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. No age-related dosage adjustment is necessary.

Renal Impairment: No dosage adjustment is recommended for patients with renal impairment

INDICATIONS AND USAGE
Gadoterate Meglumine Injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

This Important Safety Information does not include all the information needed to use Gadoterate Meglumine Injection, USP safely and effectively. Please see full prescribing information, including BOXED WARNING, for Gadoterate Meglumine Injection, USP Single Dose Vials and Pharmacy Bulk Package Vials at www.fresenius-kabi.com/us.

Gadoterate Meglumine Injection, USP

- **FDA-approved, AP Rated**
- **Macrocyclic[1,2]**
- **Ionic[1,2]**
- **Preservative Free[1,2]**
- **The container closure is not made with natural rubber latex**
- **Bioequivalent and fully substitutable to Dotarem®***

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. Gadoterate Meglumine Injection is not approved for intrathecal use.

Nephrogenic Systemic Fibrosis

GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of Gadoterate Meglumine Injection in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- **The risk for NSF appears highest among patients with:**
  - **Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or**
  - **Acute kidney injury.**
- **Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.**
- **For patients at highest risk for NSF, do not exceed the recommended Gadoterate Meglumine Injection dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.**

Unit of Sale NDC	Description	Concentration	Fill Volume (mL)	Unit of Sale
65219-080-05	Single Dose Vial	0.5 mmol per mL	5 mL	10
65219-082-10	Single Dose Vial	0.5 mmol per mL	10 mL	10
65219-084-15	Single Dose Vial	0.5 mmol per mL	15 mL	10
65219-086-20	Single Dose Vial	0.5 mmol per mL	20 mL	10
65219-088-50	Pharmacy Bulk Package	0.5 mmol per mL	100 mL	6

1. Gadoterate Meglumine Injection, USP Single Dose Vial Package Insert, August 2024
2. Gadoterate Meglumine Injection, USP Pharmacy Bulk Package Insert, August 2024
*Dotarem® is a registered trademark of Guerbet.

Ordering Information

Please contact your account representative or our Customer Service Department Monday through Friday, 7:00AM – 6:00PM (CST) at:

Toll-Free: (888) 386-1300
Fax: (800) 743-7082
E-mail: customerservice.usa@fresenius-kabi.com
For more information visit: GenericContrastAgents.com

If you are interested in establishing a new account with Fresenius Kabi USA, contact us for additional information and necessary forms.

Please see full prescribing information, including BOXED WARNING, for Gadoterate Meglumine Injection, USP Single Dose Vials and Pharmacy Bulk Package Vials at www.fresenius-kabi.com/us.

FRESENIUS KABI

Fresenius Kabi USA, LLC
Three Corporate Drive
Lake Zurich, IL 60047
Phone: 1.888.386.1300
www.fresenius-kabi.com/us

3147-GADM-02-01/24 v3.0